摘要
目的探讨不同剂量米非司酮治疗子宫内膜异位症的综合应用价值。方法将本院2010年1月—2012年1月收治的210例子宫内膜异位症患者随机分为低剂量组(6.25 mg/d)、中剂量组(12.50 mg/d)和高剂量组(25.00 mg/d),每组70例,且均治疗3个月。比较各组的疗效差异及对血清炎症因子TNF-α、IL-4、IL-8水平的影响。结果治疗3个月后,中、高剂量组血清炎症因子TNF-α、IL-4、IL-8水平显著低于低剂量组(P<0.05);3组的显效率、有效率、总有效率等均无显著差异;中、高剂量组1年后复发率略低于低剂量组,经比较无显著差异。结论 12.50 mg/d和25.00 mg/d的米非司酮治疗子宫内膜异位症具有相同的疗效且复发率低,而12.50 mg/d米非司酮进行治疗的综合应用价值高。
Objective To observe the integrated value of different doses of mifepristone for patients with endometriosis. Methods Patients with endometriosis from January 2010 to January 2012 were randomly divided into low dose group（OP, mifepristone, 6.25 mg/d, n = 70）, middle dose group（OP, mifepristone, 12.5 rag/d, n = 70） and high dose group（OP, mifepristone, 25 mg/d, n = 70）. All groups were given 3 months＇ treatment. After treatment, the efficacy and the levels of inflammatory factors TNF-α, IL-4, IL-8 were compared. Results After 3 months＇ treatment, the serum levels of inflammatory factors TNF-α, IL-4, IL-8 of the middle dose group and the high dose group were markedly lower than those of the low dose group （P 〈 0.05）. The efficacy rate and total effects and ,so on had no obvious differences between the three groups. The recurrence rate of the middle and the high lose groups after 1 year were slightly lower than that of the low dose group, The difference was not statistically significant （P 2〉 0.05）. Conclusion Use of mifepristone, 25 mg/d or 12.5 mg/d for endometriosis, has the same efficacy and low recurrence rate, and 12.5 mg/d dose group has higher integrated value.
出处
《实用临床医药杂志》
CAS
2013年第15期144-146,共3页
Journal of Clinical Medicine in Practice
